secwatch.observer — SEC 8-K summary
======================================

Issuer:     VYNE Therapeutics Inc. (VYNE)
CIK:        0001566044
Form:       8-K
Filed at:   2024-05-09T23:59:59+00:00
Accession:  0001628280-24-021971
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

VYNE reports Q1 2024 net loss of $6.2M, cash $86M; vitiligo Phase 2b trial on track
--------------------------------------------------------------------------------

- Cash, equivalents, restricted cash and marketable securities of $86.0M as of March 31; runway through end of 2025.
- Net loss $6.2M ($0.15/sh) vs $5.6M ($1.74/sh) in Q1 2023; R&D expense up 35.6% to $3.7M.
- Phase 2b trial for VYN201 in nonsegmental vitiligo to enroll ~160 subjects in 1%,2%,3% gel vs vehicle; first dose expected Q2 2024.
- IND cleared for oral BET inhibitor VYN202; Phase 1a SAD/MAD starting Q2 2024 with top-line data H2 2024.
- Top-line Phase 2b data expected mid-2025; Phase 1b trials in psoriasis and RA planned for H2 2025 if Phase 1a successful.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1566044/000162828024021971/0001628280-24-021971-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1566044/000162828024021971/mnlo-20240509.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-021971

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer